C.L. Beach

6.5k total citations · 2 hit papers
67 papers, 3.5k citations indexed

About

C.L. Beach is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, C.L. Beach has authored 67 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hematology, 30 papers in Genetics and 18 papers in Molecular Biology. Recurrent topics in C.L. Beach's work include Acute Myeloid Leukemia Research (61 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers) and Histone Deacetylase Inhibitors Research (15 papers). C.L. Beach is often cited by papers focused on Acute Myeloid Leukemia Research (61 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers) and Histone Deacetylase Inhibitors Research (15 papers). C.L. Beach collaborates with scholars based in United States, France and Australia. C.L. Beach's co-authors include Pierre Fenaux, Steven D. Gore, Valeria Santini, John F. Seymour, Alan F. List, Eva Hellström‐Lindberg, Lewis R. Silverman, Jay T. Backstrom, Ghulam J. Mufti and David R. McKenzie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

C.L. Beach

66 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

2009 1.8k citations Pierre Fenaux, Ghulam J. Mufti et al. The Lancet Oncology profile →
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

2009 698 citations Pierre Fenaux, Ghulam J. Mufti et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.L. Beach United States	15	3.0k	1.6k	894	651	422	67	3.5k
Jay T. Backstrom United States	14	3.2k 1.1×	1.7k 1.0×	1.0k 1.2×	638 1.0×	387 0.9×	46	3.8k
Norbert Gattermann Germany	26	3.6k 1.2×	1.7k 1.1×	1.6k 1.8×	672 1.0×	439 1.0×	55	4.5k
Carlo Finelli Italy	28	3.2k 1.1×	1.7k 1.1×	1.7k 2.0×	434 0.7×	315 0.7×	108	4.1k
Jalaja Potluri United States	27	2.7k 0.9×	1.6k 1.0×	1.4k 1.6×	651 1.0×	654 1.5×	79	3.7k
Michael Pfeilstöcker Austria	22	1.9k 0.6×	594 0.4×	942 1.1×	284 0.4×	266 0.6×	83	2.3k
Erin P. Demakos United States	10	1.4k 0.5×	1.0k 0.6×	474 0.5×	275 0.4×	219 0.5×	31	1.9k
Rosalie Odchimar-Reissig United States	9	1.4k 0.5×	1.0k 0.6×	434 0.5×	275 0.4×	184 0.4×	25	1.9k
Guillermo Montalban‐Bravo United States	23	1.5k 0.5×	766 0.5×	519 0.6×	363 0.6×	361 0.9×	202	1.9k
Brenton G. Mar United States	16	1.5k 0.5×	982 0.6×	667 0.7×	279 0.4×	260 0.6×	33	2.3k
Preben Philip Denmark	25	1.8k 0.6×	978 0.6×	628 0.7×	879 1.4×	474 1.1×	69	2.8k

Countries citing papers authored by C.L. Beach

Since Specialization

Citations

This map shows the geographic impact of C.L. Beach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.L. Beach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.L. Beach more than expected).

Fields of papers citing papers by C.L. Beach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.L. Beach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.L. Beach. The network helps show where C.L. Beach may publish in the future.

Co-authorship network of co-authors of C.L. Beach

This figure shows the co-authorship network connecting the top 25 collaborators of C.L. Beach. A scholar is included among the top collaborators of C.L. Beach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.L. Beach. C.L. Beach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Menezes, Daniel L., Andrew H. Wei, Hartmut Döhner, et al.. (2023). P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL. HemaSphere. 7(S3). e930876b–e930876b. 1 indexed citations

Menezes, Daniel L., Wendy L. See, Alberto Risueño, et al.. (2023). Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial. British Journal of Haematology. 201(6). 1129–1143. 3 indexed citations

Gaudy, Allison, et al.. (2023). Population Pharmacokinetics of Oral Azacitidine, and Exposure–Response Analysis in Acute Myeloid Leukemia. Clinical Pharmacology & Therapeutics. 114(4). 845–852. 4 indexed citations

Santini, Valeria, Aristoteles Giagounidis, Conrado Franco‐Villalobos, et al.. (2022). Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia. 22(9). e874–e883. 5 indexed citations

Roboz, Gail J., Farhad Ravandi, Andrew H. Wei, et al.. (2022). Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 139(14). 2145–2155. 37 indexed citations

DiNardo, Courtney D., Gautam Borthakur, Brian Ball, et al.. (2021). Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML). Blood. 138(Supplement 1). 4430–4430. 2 indexed citations

Garcia‐Manero, Guillermo, Hartmut Döhner, Andrew H. Wei, et al.. (2021). Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia. 22(4). 236–250. 16 indexed citations

Zeidan, Amer M., Isaac W. Boss, C.L. Beach, et al.. (2021). A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Advances. 6(7). 2219–2229. 64 indexed citations

Ravandi, Farhad, Andrew H. Wei, Hartmut Döhner, et al.. (2020). CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.. Journal of Clinical Oncology. 38(15_suppl). 7530–7530. 1 indexed citations

10.

Zeidan, Amer M., James D. Cavenagh, Maria Teresa Voso, et al.. (2019). Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood. 134(Supplement_1). 829–829. 60 indexed citations

11.

Garcia‐Manero, Guillermo, Bart L. Scott, Christopher R. Cogle, et al.. (2018). CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research. 72. 79–85. 15 indexed citations

12.

Döhner, Hartmut, Anna Dolnik, Lin Tang, et al.. (2018). Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 32(12). 2546–2557. 82 indexed citations

13.

García-Manero, G., L.R. Silverman, Rami S. Komrokji, et al.. (2015). 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE. Leukemia Research. 39. S28–S28. 1 indexed citations

14.

Fenaux, Pierre, John F. Seymour, Valeria Santini, et al.. (2013). Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research. 38(2). 258–262. 5 indexed citations

15.

Gore, Steven D., Pierre Fenaux, Valeria Santini, et al.. (2013). A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 98(7). 1067–1072. 102 indexed citations

16.

Gidwani, Risha, Zeba M. Khan, Pierre Fenaux, C.L. Beach, & Chris L. Pashos. (2011). A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. Journal of Medical Economics. 15(1). 145–154. 16 indexed citations

17.

Seymour, John F., Pierre Fenaux, Lewis R. Silverman, et al.. (2010). Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology. 76(3). 218–227. 86 indexed citations

18.

Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(4). 562–569. 698 indexed citations breakdown →

19.

Mufti, Ghulam J., Steven D. Gore, Valeria Santini, et al.. (2009). Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.. Blood. 114(22). 1755–1755. 8 indexed citations

20.

Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology. 10(3). 223–232. 1756 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact